Stockscreener 앱 받기
66.04
0.69%
0.45
시간 외 거래:
66.04
전일 마감가:
$65.59
열려 있는:
$65.8
하루 거래량:
675.46K
Relative Volume:
0.89
시가총액:
$4.75B
수익:
$58.89M
순이익/손실:
$-240.88M
주가수익비율:
-21.30
EPS:
-3.1
순현금흐름:
$-239.96M
1주 성능:
+2.69%
1개월 성능:
+12.77%
6개월 성능:
+123.94%
1년 성능:
+40.45%
1일 변동 폭
$63.86
$67.19
1주일 범위
$63.77
$68.80
52주 변동 폭
$19.45
$68.80
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
66.04 | 4.72B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance
Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating - MarketScreener
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Begins Dosing Patients in Phase 2 Trial of Potential Dermatitis Treatment - MarketScreener
Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis - Investing.com Australia
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis By Investing.com - Investing.com South Africa
Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewswire Inc.
Kymera Therapeutics stock hits 52-week high at 68.65 USD By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at 68.65 USD - Investing.com India
Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times
SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan
Neo Ivy Capital Management Purchases 6,079 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Will Kymera Therapeutics Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Kymera at Jefferies Conference: Targeted Protein Degradation Focus - Investing.com India
Kymera at Jefferies Conference: Targeted Protein Degradation Focus By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week HighStill a Buy? - MarketBeat
Behavioral Patterns of KYMR and Institutional Flows - news.stocktradersdaily.com
Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Stifel reiterates Buy rating on Kymera Therapeutics stock ahead of December data - Investing.com Canada
Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Why Kymera Therapeutics Inc. stock could outperform in 2025Trade Risk Summary & Weekly Top Performers Watchlists - Fundação Cultural do Pará
How to read the order book for Kymera Therapeutics Inc.Bear Alert & Low Risk High Reward Trade Ideas - newser.com
Kymera at TD Cowen Summit: Strategic Moves in Immunology By Investing.com - Investing.com Canada
What analysts say about Kymera Therapeutics Inc stockMoving Average Crossovers & Subscribe for Free Weekly Winners - earlytimes.in
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
What drives Kymera Therapeutics Inc stock priceStock Liquidity Analysis & Free Rapid Growing Investment Returns - earlytimes.in
Kymera Therapeutics stock hits 52-week high at 64.0 USD By Investing.com - Investing.com Philippines
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
Kymera at Stifel Conference: Strategic Insights on Drug Development By Investing.com - Investing.com UK
Kymera Therapeutics stock hits 52-week high at 64.0 USD - Investing.com
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Transcript : Kymera Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 11 - MarketScreener
What is HC Wainwright's Forecast for KYMR FY2025 Earnings? - MarketBeat
Equities Analysts Set Expectations for KYMR FY2025 Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen - MarketBeat
Kymera Therapeutics (KYMR) Gets a Buy from RBC Capital - The Globe and Mail
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - MSN
Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics Reports Q3 2025 Financial Results - MSN
Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera upped to overweight by Wells Fargo on upcoming data - MSN
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):